Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pancreatic Cancer-Derived Small Extracellular Vesicles Remodel Hepatic Pre-Metastatic Niche via Hybrid Epithelial-Mesenchymal States.

International journal of molecular sciences·2026
Same author

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine.

Frontiers in immunology·2026
Same author

Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma.

Journal of experimental & clinical cancer research : CR·2026
Same author

miR-369-3p Modulates LRRK2-Mediated Inflammation and Autophagy in RAW264.7 Macrophages.

International journal of molecular sciences·2026
Same author

Sustainable chemistry and preclinical characterization of RC-106·HCl: A brain-penetrant pan sigma receptor modulator for glioblastoma.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same author

Prostate-Specific Membrane Antigen (PSMA): A Potential Theranostic Biomarker in Breast Cancer.

Biomedicines·2026
Same journal

Feasibility of uniportal thoracoscopic sublobar resection without chest tube drainage: a retrospective cohort study.

Frontiers in oncology·2026
Same journal

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China.

Frontiers in oncology·2026
Same journal

Caregiver satisfaction with early integrated palliative care in oncology: secondary outcomes from the PALLiON cluster-RCT.

Frontiers in oncology·2026
Same journal

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report.

Frontiers in oncology·2026
Same journal

The multifaceted roles of mitochondria and their therapeutic transformation: a new perspective on triple-negative breast cancer treatment.

Frontiers in oncology·2026
Same journal

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study.

Frontiers in oncology·2026
查看所有相关文章

相关实验视频

Updated: Jul 27, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.7K

循环中的hsa-miR-5096预测

Martine Bocchini1, Marcella Tazzari1, Sara Ravaioli2

  • 1Immunotherapy, Cell Therapy and Biobank (ITCB), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Frontiers in oncology
|June 8, 2023
PubMed
概括
此摘要是机器生成的。

新的循环生物标志物,包括hsa-miR-5096,在接受受体放射性核素疗法 (PRRT) 的胃肠胰腺神经内分泌瘤 (GEP-NETs) 患者中预测治疗反应和预后方面表现有希望. 这些microRNA与成像发现和患者的结果相关,有助于GEP-NET管理.

关键词:
PRRT (受体放射性核酸治疗) 是一种治疗方法.这是SSTR2的SSTR2.功能成像 (正子发射断层扫描)miRNA 微RNA 的时间.胰腺神经内分泌瘤 胰腺神经内分泌瘤

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.2K

相关实验视频

Last Updated: Jul 27, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.7K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.2K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 生物标志物发现发现

背景情况:

  • 胃肠胰腺神经内分泌瘤 (GEP-NETs) 是罕见的,对于不可手术的病例,治疗选择有限.
  • 受体放射性核酸疗法 (PRRT) 显示出可变的反应,需要预后生物标志物.
  • 在PET/CT上的18F-FDG吸收表明GEP-NET中的瘤攻击性.

研究的目的:

  • 在GEP-NET中识别与18F-FDG-PET/CT状态相关的循环微RNA (miRNA).
  • 找出预测较高风险和较低响应PRRT的miRNAs.
  • 建立可测量的预后生物标志物,用于GEP-NET患者管理.

主要方法:

  • 整个miRNome下一代测序 (NGS) 在PRRT之前对来自GEP-NET患者的血样本进行分析.
  • 在18F-FDG阳性和阴性患者组之间的差异表达分析.
  • 使用实时定量PCR验证,用于无进展生存 (PFS) 的考克斯回归,以及用于miR蛋白相关性的现场杂交.

主要成果:

  • 在胰腺NET (PanNETs) 中,hsa-miR-5096,hsa-let-7i-3p和hsa-miR-4311与18F-FDG-PET/CT相关.
  • hsa-miR-5096预测了PRRT后6个月的PFS和12个月的整体生存期,并确定了预后更差的18F-FDG-PET/CT阳性PanNET.
  • hsa-miR-5096与SSTR2表达和68Gallium-DOTATOC吸收相反相关,在体外减少SSTR2.

结论:

  • hsa-miR-5096作为18F-FDG-PET/CT的生物标志物,也是泛网中PFS的独立预测因子.
  • 外体hsa-miR-5096可能会导致SSTR2异质性和PRRT耐药性.
  • 循环的miRNA为改善GEP-NET预后和治疗分层提供了潜力.